logo
Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives

Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives

WASHINGTON (AP) — Calley Means has built a following within the 'Make America Healthy Again' movement by railing against the failings of the U.S. health system, often pinning the blame on one issue: corruption.
Means, a top aide to Health Secretary Robert F. Kennedy Jr., was hired as a White House adviser in March. He has used that perch to attack the nation's leading physician groups, federal agencies and government scientists, claiming they only protect their own interests in the nation's $4.9 trillion-a-year industry.
In recent interviews, speeches and podcasts he has called the American Medical Association 'a pharma lobbying group,' labeled the Food and Drug Administration 'a sock puppet of industry,' and said federal health scientists have 'overseen a record of utter failure.'
Means, however, has his own financial stake in the sprawling health system. He's the co-founder of an online platform, Truemed, that offers dietary supplements, herbal remedies and other wellness products. Some of the vendors featured on Truemed's website are supporters of Kennedy's MAHA movement, which downplays the benefits of prescription drugs, vaccines and other rigorously tested medical products.
Kennedy has pledged to run the Department of Health and Human Services with 'radical transparency,' but Means has never had to publicly disclose his own financial details or where exactly they intersect with the policies he's advancing.
'It reeks of hypocrisy,' said Dr. Reshma Ramachandran, a health researcher at Yale University. 'In effect, he is representing another industry that is touting nonregulated products and using his platform within the government to financially benefit himself.'
In a written statement, Means said his government work has not dealt with matters affecting Truemed and has focused on issues like reforming nutrition programs and pressuring companies to phase out food dyes.
'Pursuing these large-scale MAHA goals to make America healthy has been the sole focus in my government work,' Means said.
Truemed helps users take tax-free money out of their health savings accounts, or HSAs, to spend on things that wouldn't normally qualify as medical expenses, such as exercise equipment, meal delivery services and homeopathic remedies — mixtures of plants and minerals based on a centuries-old theory of medicine that's not supported by modern science.
The business model caught the attention of the IRS last year, which issued an alert: 'Beware of companies misrepresenting nutrition, wellness and general health expenses as medical care.'
Truemed co-founder and CEO, Justin Mares, said in a statement the company is 'in full alignment' with IRS guidelines.
'Truemed enables patients to work with providers to use medical funds for root cause interventions like exercise and vitamin D to reverse disease under current law,' Mares said.
The full extent of Means' potential conflicts — including his personal investments— are unclear because of his status as a special government employee.
Unlike presidential appointees and other senior officials, special government employees are temporary staffers who do not have to leave companies or sell investments that could be impacted by their work. Also, their financial disclosure forms are shielded from public release.
'It's a big problem,' says Richard Painter, a former White House ethics lawyer under George W. Bush now at the University of Minnesota. Painter and other experts have raised alarms over a whirlwind of Trump administration actions to dismantle the government's public integrity guardrails.
Still, part-time government employees are subject to the same law that bars all federal staffers from working on issues that could directly benefit their finances. When such cases arise, they must recuse themselves or risk criminal penalties.
Means regularly opines on matters before HHS, including rethinking the use of drugs for depression, weight loss, diabetes and other conditions. Recently he's been promoting a new government report that calls for scaling back prescription medications in favor of exercise, dietary changes and other alternatives.
'If we rely less on our medical system, less on drugs, it necessitates the spiritual, cultural conversation about what we're doing to our children's bodies,' Means said in a recent podcast appearance.
Experts note that government ethics rules are intended to both prevent financial conflict violations, but also the appearance of such conflicts that might undermine public trust in government.
'If I were running the ethics office over at HHS, I sure as heck wouldn't want anybody going around giving interviews and speeches about government matters that could have an effect on their own financial interests,' Painter said.
A rising star in the MAHA movement
Means' rapid rise reflects the seeming contradictions within the MAHA movement itself, which urges followers to distrust both big corporations and the government agencies which regulate them.
Means rails against big pharma and food conglomerates, two industries that he says he spent years working for as a consultant in Washington.
Means has no medical training. A graduate of Harvard Business School, he previously ran a bridal gown startup with his wife.
He traces his passion for health care reform to the death of his mother from pancreatic cancer in 2021. Shortly thereafter, Means and his sister, Dr. Casey Means, took psychedelics together and had 'a mind-blowing, life-changing experience,' which led them to co-author a wellness book, launch separate health startups and begin appearing on podcasts.
Casey Means was recently nominated to be surgeon general and has faced scrutiny over her qualifications, including an unfinished medical residency.
Asked about her nomination, President Donald Trump said: 'Bobby thought she was fantastic,' adding that he did not know her.
Meanwhile, her brother has stepped up his rhetoric for the MAHA agenda, recently declaring that Kennedy has 'a spiritual mandate to reform our broken system.'
While promoting the administration's accomplishments, Means does not shy away from plugging his own brand or those of his business partners.
When asked to offer health advice to listeners of a sports podcast, Outkick The Show, in April, Means said: 'Read our book, 'Good Energy.''
He also recommended blood tests sold by Function Health, which provides subscription-based testing for $500 annually. The company was cofounded by Dr. Mark Hyman, a friend of Kennedy and an investor in Truemed, which also offers Hyman's supplements through its platform. Casey Means is also an investor in Hyman's company.
'If you're sick, most likely you have some kind of nutrient deficiency, some kind of biomarker that you can actually then target with your diet and your supplements,' Calley Means said.
Like dietary supplements, the marketing claims on laboratory tests sold by Hyman are not approved by the FDA. The agency has warned for years about the accuracy of such tests and tried to start regulating them under President Joe Biden.
Experts say MAHA entrepreneurs like Hyman are following a playbook common to the wellness industry: Identify a health concern, market a test to diagnose it and then sell supplements or other remedies to treat it.
'It ends up favoring these products and services that rest on flimsy grounds, at the expense of products that have actually survived a rigorous FDA approval process,' said Dr. Peter Lurie, a former FDA official who is now president of the Center for Science in the Public Interest.
Many of the items sold via Truemed, including sweat tents, cold plunge tanks and light therapy lamps, wouldn't typically qualify as medical expenses under rules for HSAs, tax-free accounts created by Congress to manage medical costs.
The IRS generally states that HSA purchases must help diagnose, cure, treat, mitigate or prevent disease.
Truemed allows users to request a 'letter of medical necessity' from a doctor, stating that the product in question could have medical value for them. Like other telehealth services, there's usually no real-time communication with the patient. The physician reviews a 'simple survey solution,' filled out by the Truemed user, according to the company's website.
Industry representatives say customers should be careful.
'You need to be prepared to defend your spending habits under audit,' said Kevin McKechnie, head of the American Bankers Association's HSA council. 'Companies are popping up suggesting they can help you manage that process and maybe they can — so the debate continues.'
Americans have an estimated $147 billion in HSA accounts, a potential windfall for companies like Truemed that collects fees for transactions made using their platforms.
Means sees an even bigger opportunity — routing federal funds out of government programs and into more HSAs.
'The point of our company is to steer medical dollars into flexible spending,' Means told fitness celebrity Jillian Michaels, on her podcast last year. 'I want to get that $4.5 trillion of Medicare, Medicaid, everything into a flexible account.'
Who benefits most from HSAs?
Means' pitch for expanding HSAs echoes two decades of Republican talking points on the accounts, which were created in 2003 to encourage Americans in high-deductible plans to be judicious with their health dollars.
But HSAs have not brought down spending, economists say. They are disproportionately used by the wealthiest Americans, who have more income to fund them and a bigger incentive to lower their tax rate.
Americans who earn more than $1 million annually are the group most likely to make regular HSA contributions, according to an analysis by the nonprofit Center on Budget and Policy Priorities. More than half Americans with HSAs have balances less than $500.
Trump's 'One Big Beautiful Bill' would further expand HSA purchases, making gym memberships and other fitness expenses eligible for tax-free spending. That provision alone is expected to cost the government $10 billion in revenue.
'These are really just tax breaks in the guise of health policy that overwhelmingly benefit people with high incomes,' said Gideon Lukens, a former White House budget official during the Obama and Trump administrations, now with the Center on Budget and Policy Priorities.
Expanding HSA eligibility was listed as a goal for a coalition of MAHA entrepreneurs and Truemed partners, founded by Means, which lobbied Congress last year, according to the group's website.
Means said in a statement that the group focused only on broad topics like 'health care incentives and patient choice — but did not lobby for specific bills.'
In total, the HSA expansions in Trump's bill are projected to cost the federal government $180 billion over the next 10 years. As HSAs expand to include more disparate products and services, Lukens says the U.S. government will have fewer dollars to expand medical coverage through programs like Medicaid.
'We have a limited amount of federal resources and the question is whether we want to spend that on health and wellness products that may or may not be helpful for wealthy people,' Lukens said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Medscape

timean hour ago

  • Medscape

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology (ASCO) 2025 annual meeting. The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA (ctDNA). METHODOLOGY: The phase 3 CheckMate 816 trial has shown that compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint. The median follow-up duration was 68.4 months. TAKEAWAY: The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% (hazard ratio [HR], 0.72; P = .048). = .048). Among patients who received the combination therapy, the 5-year overall survival rate was 95.3% for those who achieved a pathological complete response vs 55.7% for those who did not. Overall, 24% of patients in the nivolumab group achieved a pathological complete response vs only 2.2% in the chemotherapy group. ctDNA clearance before surgery was a strong prognostic indicator, regardless of treatment. At 5 years, overall survival was 75.0% among patients with ctDNA clearance vs 52.6% in those without (HR for death, 0.38 in the nivolumab group and 0.39 in the chemotherapy-only group). The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths related to a trial treatment. IN PRACTICE: 'In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,' the authors wrote. 'These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient's life when paired with the curative potential of surgical resection.' SOURCE: This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland, was published online in The New England Journal of Medicine and presented at ASCO. LIMITATIONS: Although the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings. DISCLOSURES: This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb.

AMA Calls for ACIP Answers, Stable Federal Funding
AMA Calls for ACIP Answers, Stable Federal Funding

Medscape

time2 hours ago

  • Medscape

AMA Calls for ACIP Answers, Stable Federal Funding

Leaders and delegates at this week's American Medical Association (AMA) annual meeting called for more stable funding for medical care and research, and a US Senate investigation into unprecedented changes to a federal vaccine advisory panel. AMA delegates passed an emergency resolution asking for that investigation after US Department of Health and Human Services Secretary Robert F. Kennedy Jr earlier this week removed all 17 members of the Advisory Committee on Immunization Practices (ACIP), replacing them with eight new members, some regarded as vaccine skeptics. The resolution also directs AMA to send a letter asking Kennedy to immediately reverse the changes. Jason M. Goldman, MD, president of the American College of Physicians said at the meeting that Kennedy's action puts at risk insurance coverage for vaccines. ACIP's recommendations influence insurance coverage and vaccine uptake. 'As physicians, we must be the voice for our patients,' said Goldman. 'We must be the voice for science, evidence, and knowledge, and we must make sure that our institutions are protected.' Other delegates pressed the AMA to fight back against deep cuts to federal funding for healthcare and medical research. In his inaugural speech on Tuesday as AMA president, Bobby Mukkamala, MD, an otolaryngologist, said the 'importance of access to physician care is very much on my mind.' 'We cannot lose sight of what medicine and science have achieved in our lifetimes, and we cannot abandon this progress and endanger the health of millions whose illnesses could have been treated had we stayed on course,' Mukkamala said. Congressional Republicans have proposed cutting Medicaid spending and reducing subsidies for plans sold by exchanges created by the Affordable Care Act. Separately, the Trump administration has proposed a roughly 40% cut, or almost $18 billion, in the annual funding of the National Institutes of Health for fiscal 2026, the budget year starting in October. Mukkamala also called for efforts to reduce the administrative burden of prior authorization and to address Medicare physician payments, which have not kept up with inflation in recent years. More Transparency for Artificial Intelligence (AI) in Medicine The AMA also adopted policies regarding AI-driven tools and guidance for physicians regarding corporate investment in their practices. One policy calls for independent third parties to determine whether an AI tool for clinicians is 'explainable' — that it can explain to users its decisions and the evidence behind them. The new AMA policy calls for more transparency regarding these tools, including disclosure of their algorithms. Physicians at the conference raised concerns about AI-based tools making errors that could potentially harm patients and leave clinicians liable for the tools' flaws. AMA members' concerns included the potential for AI hallucinations about billing codes to leave a busy physician at risk for allegations of fraud. Among those who pushed for the AMA to adopt new policies on AI-driven tools was Jennifer Bryan, MD, chair of the Mississippi delegation to the AMA and president of the Mississippi State Medical Association. Decisions made at this AMA meeting will help physicians know when 'AI informs clinical decisions and exactly how confident the AI is in its recommendations,' Bryan told Medscape Medical News in an email. 'This is a big step forward in not just setting standards today but shaping responsible AI practices in medicine for years to come.' Corporate Intrusion The AMA delegates also voted to strengthen guidance for physicians regarding corporate or private equity investment in their practices. Corporate investment can offer an alternative to selling a practice to a hospital or health system, AMA said. These kinds of arrangements can include private or public for-profit companies, investment firms, and insurance companies. Physicians may benefit from these arrangements by being freed of some business and administrative responsibilities to spend more time with patients. But such arrangements may also pose risks, including the loss of independent authority over clinical decisions and operations, the AMA said. AMA's updated guidance recommends that decisions that should remain in the ultimate control of the physicians partnered with other entities include: Determining which diagnostic tests are appropriate for patients. Determining the need for referral or consultation with another clinician. Determining how many patients a physician should see or how many hours a physician should work. Determining the content of patient medical records. Making decisions regarding coding and billing procedures for patient care services.

Taiwan Goes All-In for BIO in Boston: 2025's Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships
Taiwan Goes All-In for BIO in Boston: 2025's Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships

Yahoo

time2 hours ago

  • Yahoo

Taiwan Goes All-In for BIO in Boston: 2025's Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships

BOSTON, June 11, 2025 /PRNewswire/ -- Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and supported by various government agencies, will attend the BIO International Convention 2025, taking place June 16–19 in Boston. The Taiwan Pavilion, themed "Taiwan, Your Best Partner in Asia," brings together 35 companies, one industry association, and six research institutes to showcase advancements in AI-driven healthcare, biomanufacturing, and precision medicine. Building on BIO 2024's success with 19,608 attendees and 61,508 business matchmaking meetings, Taiwan aims to strengthen its role as a global biotech leader by highlighting innovations and expanding international partnerships. The Taiwan Pavilion highlights "Full-Age Precision Medicine," showcasing over 50 technologies addressing healthcare needs across all life stages. Key innovations - Taiwan's expertise in AI enhances medical informatics and smart healthcare solutions, while its biomanufacturing supports global pharmaceutical production. These advancements position Taiwan as a leader in regenerative medicine, medical devices, and contract development and manufacturing organizations (CDMOs). Adding further momentum to Taiwan's presence at the convention, two Taiwanese biotech startups — AnHorn Medicines and Pharmasaga Company Limited — have been selected as finalists in the Start-Up Stadium, a global competition that drew 57 teams from around the world. Their selection reflects the rising profile and competitiveness of Taiwan's biotech sector and provides finalists with a valuable opportunity to engage with global pharmaceutical leaders and venture capitalists, potentially leading to strategic partnerships and funding opportunities. Taiwan's BIO 2025 Key Events to Attend – Tuesday, June 17 Global Innovation Hub – Taiwan (3:15–3:30 p.m., Meeting Room 152):A focused session spotlighting Taiwan's biomedical breakthroughs and collaboration opportunities, reflecting the broad coalition behind Taiwan's delegation across industry, government, academia, and clinical sectors. Taiwan Pavilion Networking Event (4:00–5:00 p.m., Booths 1545 & 1645):An open networking event welcoming global biotech leaders, featuring a Happy Hour and showcasing next-generation technologies, promising products, and emerging opportunities for cross-border collaboration. The Taiwan Pavilion at BIO 2025 (Booth No. 1545 & 1645) showcases numerous biotech companies. Coordinated by BPIPO, it promotes global partnerships in biotech, CDMO, and precision health. Exhibited technologies include cell and gene therapy, novel drug development, smart medical devices, and integrated solutions for all stages of healthcare. As BIO 2025 approaches, Taiwan's delegation prepares to showcase its biotech strengths and global strategy to shape the industry's future. More details and delegation links are available at or by contacting BPIPO. View original content to download multimedia: SOURCE The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store